sf2a-tt15
Vaccineexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 6, 2020 (NCT04602975)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ShigellaImmunity, active
Shigella immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04602975 | Phase 2 | Oct 6, 2020 | Bill and Melinda Gates Foundation, ClinWin Research, Henry M. Jackson Foundation for the Advancement of Military Medicine, Institut Pasteur, Kenya Medical Research Institute, Parexel, United States Army, Wellcome Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| ClinWin Research | For profit | 1 | 0 | 1 | 2020 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Institut Pasteur | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Parexel | For profit | 1 | 0 | 1 | 2020 |
| United States Army | Government | 1 | 0 | 1 | 2020 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2020 |
8 organizations
Page 1 / 1